Fig. 5: In vivo behaviors of CAA-PEG NSs and its multi-modal therapeutic efficacy for CRC treatment.
From: In situ valence-transited arsenic nanosheets for multi-modal therapy of colorectal cancer
Free ICG or ICG-labelled CAA-PEG NSs -mediated fluorescence distribution in CT-26 tumor-bearing mice and main organs (a) and their semi-quantitative analysis (b, c) (Data are presented as mean values +/− SD, n = 3 mice. Unpaired t-tests for each comparison were used. P values were presented in absolute value in the figures). d Photoacoustic images of CT-26 tumor-bearing mice before (control) and after intravenous injection of CAA-PEG NSs at 4, 8, 12, and 24 h. e Tumor temperature changes after 8 h intravenous injection of CAA-PEG NSs and then upon laser irradiation for 10 min. Data are presented as mean values +/− SD, n = 3 mice. One-way ANOVA with Tukey’s Multiple Comparison Test was used to compare the mean of each group with the mean of each other groups. P values were presented in absolute value in the figures. Tumor size (f), survival curve (g) and body weight (Fig. S3o) of CT-26 tumor-bearing mice after various treatments (Data are presented as mean values +/− SD, n = 5 mice. For (f) One-way ANOVA with Dunnett’s Multiple Comparison Test was used to compare each group with the Control groups. P values were presented in absolute value in the figures. Significant differences in survival (g) were calculated by the Mantel–Cox test and P values were presented in absolute value in the figure). h Immunofluorescent staining assays (P53 and CBS) were performed on tumor sections after different drug treatments.
